MMF surpasses cyclophosphamide in lupus nephritis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1516, 2005-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low- vs high-dose cyclophosphamide in lupus nephritis

Inpharma, Vol. 1, Iss. 1359, 2002-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis

By Brugos B. Sebestyen L. Tarr T. Vincze Z.

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 69, Iss. 6, 2014-06 ,pp. : 442-444

Govi-Verlag

Access to resources Recommend Favorite

Clinical Pathway for Monthly Pulse Intravenous Cyclophosphamide Therapy for Lupus Nephritis

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 42, Iss. 4, 2012-12 ,pp. : 278-282

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cyclophosphamide: Miscarriage in patients with lupus nephritis?: 2 case reports

Reactions Weekly, Vol. 1, Iss. 1365, 2011-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Low-dose fludarabine plus cyclophosphamide is effective in patients with proliferative lupus nephritis, but is associated with considerable adverse outcomes

Inpharma, Vol. 1, Iss. 1600, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite